Liberate Bio has primate data and a new CMO. Can its in vivo CAR-M platform make the clinical leap?
Liberate Bio appoints Steven Bernstein as CMO as LIB820 advances toward a first human study in systemic sclerosis and in vivo CAR-M validation.
Pharma & Biotech
Pharma & Biotech
GSK’s Exdensur wins FDA nod for severe asthma: Can twice-yearly dosing reset the biologics playbook?
GSK’s Exdensur has been approved by the FDA as the first biannual biologic for severe asthma. Find out what this means for patients, payers, and rivals.